Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial

被引：0
|
作者：
Perreault, Leigh
Davies, Melanie J.
Frias, Juan P.
Laursen, Peter N.
Lingvay, Ildiko
Machineni, Sriram
Varbo, Anette
Wilding, John
Wallenstein, Signe O. R.
Le Roux, Carel
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-81-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
81-OR
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
    Ping Zhong
    Hai Zeng
    Miaochun Huang
    Wenbin Fu
    Zhixia Chen
    Endocrine, 2022, 75 : 718 - 724
  • [22] Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes: STEP 2 post-hoc analysis
    Deanfield, J. E.
    Davies, M.
    Garvey, W. T.
    Jeppesen, O. K.
    Khalid, U.
    Kosiborod, M.
    Kushner, R. F.
    Laursen, P. N.
    Rubino, D. M.
    Verma, S.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 249 - 249
  • [23] Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis
    Kushner, Robert F.
    Davies, Melanie J.
    Deanfield, John
    Garvey, W. Timothy
    Jeppesen, Ole
    Khalid, Usman
    Kosiborod, Mikhail N.
    Laursen, Peter N.
    Rubino, Domenica
    Verma, Subodh
    DIABETES, 2021, 70
  • [24] Continued Semaglutide 2.4 mg Once Weekly Improved Health Related Quality of Life in the STEP 4 Trial
    Sharma, Arya
    Meincke, Henrik
    Jensen, Camilla
    Kushner, Robert
    Pedersen, Sue
    Rubino, Domenica
    Tran, Marie
    Wharton, Sean
    Bjorner, Jakob
    OBESITY, 2021, 29 : 9 - 10
  • [25] Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg
    Kelly, Aaron S.
    Arslanian, Silva
    Hesse, Dan
    Iversen, Aske Thorn
    Koerner, Antje
    Schmidt, Signe
    Sorrig, Rasmus
    Weghuber, Daniel
    Jastreboff, Ania M.
    OBESITY, 2023, 31 (08) : 2139 - 2149
  • [26] Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria
    Chetty, Ashwin K.
    Khunte, Mihir
    Lu, Yuan
    Chen, Alissa S.
    AMERICAN HEART JOURNAL, 2024, 278
  • [27] Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity
    Wilkinson, Lua
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Batterham, Rachel L.
    Garvey, W. Timothy
    OBESITY, 2023, 31 (09) : 2249 - 2259
  • [28] Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
    McGowan, Barbara M.
    Bruun, Jens M.
    Capehorn, Matt
    Pedersen, Sue D.
    Pietilainen, Kirsi H.
    Muniraju, Hanna Angelene Kudiyanur
    Quiroga, Maria
    Varbo, Anette
    Lau, David C. W.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (09): : 631 - 642
  • [29] Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial
    Dimitriadis, Georgios K.
    Batterham, Rachel
    Bhatta, Meena
    Holst-Hansen, Thomas
    Kandler, Kristian
    Rigas, Georgia
    Garvey, W. Timothy
    OBESITY SURGERY, 2023, 33 : S119 - S119
  • [30] Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis
    He, Ke
    Guo, Qing
    Zhang, Haijuan
    Xi, Wang
    Li, Jingxin
    Jing, Zeng
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 722 - 726
12345